ION expands ETF trading capabilities with Tradeweb integration
Director Arani Bose of Penumbra Inc (NASDAQ:PEN) sold 7,500 shares of common stock on November 25, 2025, at a weighted average price of $300.19, for a total value of $2.25 million. The transactions were executed in multiple trades with prices ranging from $300.00 to $300.64. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan. The sale occurred as Penumbra trades near its 52-week high of $310, with the stock showing a strong 21.2% return over the past year according to InvestingPro data.
On November 26, 2025, Bose also made a gift of 1,799 shares.
Following these transactions, Bose directly owns 558 shares of Penumbra, a portion of which is subject to vesting, and indirectly owns 273,462 shares through Bose Family Holdings II, LLC. Penumbra, with a market capitalization of $11.58 billion, currently trades at a P/E ratio of 71.8 and is considered overvalued according to InvestingPro Fair Value estimates. Despite this, the company maintains a "GREAT" financial health rating and analysts expect net income growth this year. For deeper insights on Penumbra and 1,400+ other stocks, check out the comprehensive Pro Research Reports available on InvestingPro.
In other recent news, Penumbra reported a strong third quarter for 2025, with revenue reaching $354.7 million, representing a 17.8% year-over-year increase and surpassing the forecast of $340.91 million. This performance led the company to raise its 2025 revenue guidance. The thrombectomy segment showed notable growth, improving to 15% at constant currency, up from 13% in the previous quarter. Needham reiterated its Buy rating on Penumbra, setting a price target of $326.00, following the impressive financial results.
Truist Securities also maintained a Buy rating, raising its price target to $312.00, citing strong growth in the venous thromboembolism segment, which saw a 34% increase. U.S. Embolization & Access outperformed expectations, contributing to a 3.5% revenue beat and earnings per share upside. Evercore ISI adjusted its price target to $286.00, maintaining an Outperform rating, as Penumbra’s organic revenue growth of 17% to $355 million exceeded Street estimates by 4%.
The Embolization segment experienced a 20.8% organic growth, surpassing expectations by 15%, with U.S. Embolization up 29% organically. These recent developments reflect positively on Penumbra’s performance and future prospects, as noted by various analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.